Immunoembolization for the Treatment of Uveal Melanoma Hepatic Metastases

Overview

Journal Semin Intervent Radiol

Specialty Radiology

Date 2024 Mar 18

PMID 38495266

Authors

Carin F Gonsalves

Affiliations

Soon will be listed here.

Abstract

Uveal melanoma is the most common primary intraocular tumor in adults. Approximately 50% of patients develop metastatic disease despite successful treatment of the primary eye tumor. The liver is the most common site of metastatic disease occurring in more than 90% of patients. Clinical prognosis is dependent on the ability to control the growth of liver tumors. Locoregional therapies play an important role in stabilizing liver metastases, prolonging survival for patients with metastatic uveal melanoma. As overall survival is prolonged, the development of extrahepatic disease becomes more common. Immunoembolization, a form of liver-directed therapy, not only focuses on treating hepatic metastases by stimulating the local immune system to suppress the growth of liver tumors, but it potentially generates a systemic immune response delaying the growth of extrahepatic metastases as well. The following article discusses immunoembolization for the treatment of metastatic uveal melanoma including the rationale, mechanism of action, indications, contraindications, outcomes, and associated toxicities.

References

Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K . Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A. 1993; 90(8):3539-43. PMC: 46336. DOI: 10.1073/pnas.90.8.3539. View

Heppt M, Heinzerling L, Kahler K, Forschner A, Kirchberger M, Loquai C . Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition. Eur J Cancer. 2017; 82:56-65. DOI: 10.1016/j.ejca.2017.05.038. View

Kaliki S, Shields C . Uveal melanoma: relatively rare but deadly cancer. Eye (Lond). 2016; 31(2):241-257. PMC: 5306463. DOI: 10.1038/eye.2016.275. View

Ulmer A, Beutel J, Susskind D, Hilgers R, Ziemssen F, Luke M . Visualization of circulating melanoma cells in peripheral blood of patients with primary uveal melanoma. Clin Cancer Res. 2008; 14(14):4469-74. DOI: 10.1158/1078-0432.CCR-08-0012. View

Akyuz M, Yazici P, Dural C, Yigitbas H, Okoh A, Bucak E . Laparoscopic management of liver metastases from uveal melanoma. Surg Endosc. 2015; 30(6):2567-71. DOI: 10.1007/s00464-015-4527-9. View

Mariani P, Almubarak M, Kollen M, Wagner M, Plancher C, Audollent R . Radiofrequency ablation and surgical resection of liver metastases from uveal melanoma. Eur J Surg Oncol. 2016; 42(5):706-12. DOI: 10.1016/j.ejso.2016.02.019. View

Aoyama T, Mastrangelo M, Berd D, Nathan F, Shields C, Shields J . Protracted survival after resection of metastatic uveal melanoma. Cancer. 2000; 89(7):1561-8. DOI: 10.1002/1097-0142(20001001)89:7<1561::aid-cncr21>3.0.co;2-r. View

Field M, Decatur C, Kurtenbach S, Gezgin G, van der Velden P, Jager M . PRAME as an Independent Biomarker for Metastasis in Uveal Melanoma. Clin Cancer Res. 2016; 22(5):1234-42. PMC: 4780366. DOI: 10.1158/1078-0432.CCR-15-2071. View

Yamamoto A, Chervoneva I, Sullivan K, Eschelman D, Gonsalves C, Mastrangelo M . High-dose immunoembolization: survival benefit in patients with hepatic metastases from uveal melanoma. Radiology. 2009; 252(1):290-8. PMC: 6944074. DOI: 10.1148/radiol.2521081252. View

10.

Seedor R, Orloff M, Sato T . Genetic Landscape and Emerging Therapies in Uveal Melanoma. Cancers (Basel). 2021; 13(21). PMC: 8582814. DOI: 10.3390/cancers13215503. View

11.

Shields C, Shields J . Ocular melanoma: relatively rare but requiring respect. Clin Dermatol. 2008; 27(1):122-33. DOI: 10.1016/j.clindermatol.2008.09.010. View

12.

Algazi A, Tsai K, Shoushtari A, Munhoz R, Eroglu Z, Piulats J . Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. Cancer. 2016; 122(21):3344-3353. PMC: 5767160. DOI: 10.1002/cncr.30258. View

13.

Yoshida T, Sakon M, Umeshita K, Kanai T, Miyamoto A, Takeda T . Appraisal of transarterial immunoembolization for hepatocellular carcinoma: a clinicopathologic study. J Clin Gastroenterol. 2001; 32(1):59-65. DOI: 10.1097/00004836-200101000-00014. View

14.

Sato T . Locoregional management of hepatic metastasis from primary uveal melanoma. Semin Oncol. 2010; 37(2):127-38. DOI: 10.1053/j.seminoncol.2010.03.014. View

15.

Patel K, Sullivan K, Berd D, Mastrangelo M, Shields C, Shields J . Chemoembolization of the hepatic artery with BCNU for metastatic uveal melanoma: results of a phase II study. Melanoma Res. 2005; 15(4):297-304. DOI: 10.1097/00008390-200508000-00011. View

16.

Yang J, Manson D, Marr B, Carvajal R . Treatment of uveal melanoma: where are we now?. Ther Adv Med Oncol. 2018; 10:1758834018757175. PMC: 5824910. DOI: 10.1177/1758834018757175. View

17.

Aronow M, Topham A, Singh A . Uveal Melanoma: 5-Year Update on Incidence, Treatment, and Survival (SEER 1973-2013). Ocul Oncol Pathol. 2018; 4(3):145-151. PMC: 5939716. DOI: 10.1159/000480640. View

18.

Balasubramanya R, Selvarajan S, Cox M, Joshi G, Deshmukh S, Mitchell D . Imaging of ocular melanoma metastasis. Br J Radiol. 2016; 89(1065):20160092. PMC: 5124918. DOI: 10.1259/bjr.20160092. View

19.

Valsecchi M, Mizue Terai , Eschelman D, Gonsalves C, Chervoneva I, Shields J . Double-blinded, randomized phase II study using embolization with or without granulocyte-macrophage colony-stimulating factor in uveal melanoma with hepatic metastases. J Vasc Interv Radiol. 2015; 26(4):523-32.e2. PMC: 4417549. DOI: 10.1016/j.jvir.2014.11.037. View

20.

van den Bosch T, van Beek J, Vaarwater J, Verdijk R, Naus N, Paridaens D . Higher percentage of FISH-determined monosomy 3 and 8q amplification in uveal melanoma cells relate to poor patient prognosis. Invest Ophthalmol Vis Sci. 2012; 53(6):2668-74. DOI: 10.1167/iovs.11-8697. View